Patheon expands Pharmaceutical Development Services capacity in Canada

Published: 24-Oct-2008
Regulatory Research & Development

Patheon, a global provider of drug development and manufacturing services, has opened a new Pharmaceutical Development Services (PDS) suite at the Whitby Development Centre in Canada.


Patheon, a global provider of drug development and manufacturing services, has opened a new Pharmaceutical Development Services (PDS) suite at the Whitby Development Centre in Canada.

The 2,500ft2 suite includes a designated area for the small-scale development and manufacturing of solid dosage forms for customers' early clinical study needs. Designed to give rapid response, the facility is GMP-compliant for manufacturing products for Phase I/II clinical studies.

By providing clinical trial materials for First Time in Human (Phase I) studies, the suite will contribute to Patheon's Quick To Clinic offering. The new facility will also add early-phase pharmaceutical development and manufacturing capacity, with a manufacturing scale of 1kg to 10kg.

The suite has multiple labs with the capability for small-scale dosage form development, as well as the manufacture of powder-in-bottle, tablets (immediate and modified release), capsules, oral liquids, and nasal sprays.

"This new facility will significantly strengthen Patheon's competitiveness in the pharmaceutical and biotechnology early development arena," said Dr Colin Minchom, vice-president, Pharmaceutical Development Services, Canada.

See more

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Read more
Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Drug Delivery

Tiziana receives grant for intranasal anti-CD3 monoclonal antibody therapy for spinal cord injury

The US Department of Defense awarded the biotechnology company a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI)
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Subscribe now